{"database": "openregs", "table": "documents", "is_view": false, "human_description_en": "where docket_id = \"FDA-2012-D-0307\" and posted_year = 2017 sorted by posted_date descending", "rows": [["FDA-2012-D-0307-0023", "FDA", "FDA-2012-D-0307", "Reference 37-Regulation (EC) No 999_2001 of EU Parliament re Amendment to \u2018\u2018Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;\u2019\u2019 Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2020-02-25T15:38:29Z", null, 0, 0, "0900006482d5883c"], ["FDA-2012-D-0307-0013", "FDA", "FDA-2012-D-0307", "Reference 01 - Revised Preventive Measures to Reduce the Possible Risk of Transmission of CJD and vCJD by blood and blood products re Amendment to \u2018\u2018Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;\u2019\u2019 Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2017-12-22T16:24:28Z", null, 0, 0, "0900006482d5882c"], ["FDA-2012-D-0307-0010", "FDA", "FDA-2012-D-0307", "Amendment to \u2018\u2018Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;\u2019\u2019 Draft Guidance for Industry; Availability", "Notice", "Notice of Availability", "2017-12-22T05:00:00Z", 2017, 12, "2017-12-22T05:00:00Z", "2018-03-23T03:59:59Z", "2018-01-06T02:01:16Z", "2017-27569", 0, 0, "0900006482d56ac6"], ["FDA-2012-D-0307-0016", "FDA", "FDA-2012-D-0307", "Referecne 28-Gregori_et_al-2011-Transfusion re Amendment to \u2018\u2018Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;\u2019\u2019 Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2020-02-25T15:36:55Z", null, 0, 0, "0900006482d58830"], ["FDA-2012-D-0307-0021", "FDA", "FDA-2012-D-0307", "Reference 35-Schlicter S.J. (1997)TRAP Study re Amendment to \u2018\u2018Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;\u2019\u2019 Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2020-02-25T15:37:58Z", null, 0, 0, "0900006482d58838"], ["FDA-2012-D-0307-0015", "FDA", "FDA-2012-D-0307", "Reference 25-Yang_et_al-2017-Transfusion re Amendment to \u2018\u2018Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;\u2019\u2019 Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2020-02-25T15:36:39Z", null, 0, 0, "0900006482d5882e"], ["FDA-2012-D-0307-0020", "FDA", "FDA-2012-D-0307", "Reference 34-King_LR reduced RBC rxn_Tx_'04 re Amendment to \u2018\u2018Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;\u2019\u2019 Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2020-02-25T15:37:48Z", null, 0, 0, "0900006482d58835"], ["FDA-2012-D-0307-0011", "FDA", "FDA-2012-D-0307", "Amendment to \u2018\u2018Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;\u2019\u2019 Draft Guidance for Industry; Availability", "Other", "Guidance", "2017-12-22T05:00:00Z", 2017, 12, "2017-12-22T05:00:00Z", "2018-03-23T03:59:59Z", "2024-11-07T01:15:24Z", null, 1, 0, "0900006482d58385"], ["FDA-2012-D-0307-0019", "FDA", "FDA-2012-D-0307", "Reference 32-Transfusion-medicine-epidemiology-review-tmer re Amendment to \u2018\u2018Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;\u2019\u2019 Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2020-02-25T15:37:39Z", null, 0, 0, "0900006482d58833"], ["FDA-2012-D-0307-0018", "FDA", "FDA-2012-D-0307", "Reference 31-McCutcheon_et_al-2011-PloSOne re Amendment to \u2018\u2018Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;\u2019\u2019 Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2020-02-25T15:37:23Z", null, 0, 0, "0900006482d58832"], ["FDA-2012-D-0307-0022", "FDA", "FDA-2012-D-0307", "Referenec 36-Bowden_LR v seroneg_Blood '95 re Amendment to \u2018\u2018Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;\u2019\u2019 Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2020-02-25T15:38:22Z", null, 0, 0, "0900006482d5883b"], ["FDA-2012-D-0307-0024", "FDA", "FDA-2012-D-0307", "Reference 38-FDA Transmissible Spongiform Encephalopathies Advisory Committee re Amendment to \u2018\u2018Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;\u2019\u2019 Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2020-02-25T15:38:38Z", null, 0, 0, "0900006482d5883d"], ["FDA-2012-D-0307-0014", "FDA", "FDA-2012-D-0307", "Reference 19-Swiss Med Wkly re Amendment to \u2018\u2018Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;\u2019\u2019 Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2017-12-22T16:24:59Z", null, 0, 0, "0900006482d5882d"], ["FDA-2012-D-0307-0017", "FDA", "FDA-2012-D-0307", "Reference 29-Harvey_et_al-2015-Transfusion re Amendment to \u2018\u2018Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;\u2019\u2019 Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2020-02-25T15:37:08Z", null, 0, 0, "0900006482d58831"], ["FDA-2012-D-0307-0012", "FDA", "FDA-2012-D-0307", "Reference List re Amendment to \u2018\u2018Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;\u2019\u2019 Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2017-12-22T16:24:07Z", null, 0, 0, "0900006482d587fd"]], "truncated": false, "filtered_table_rows_count": 15, "expanded_columns": [], "expandable_columns": [[{"column": "docket_id", "other_table": "dockets", "other_column": "id"}, "title"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"docket_id\" = :p0 and \"posted_year\" = :p1 order by posted_date desc limit 101", "params": {"p0": "FDA-2012-D-0307", "p1": "2017"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2012-D-0307&posted_year=2017", "results": [{"value": "FDA", "label": "FDA", "count": 15, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2012-D-0307&posted_year=2017&agency_id=FDA", "selected": false}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2012-D-0307&posted_year=2017", "results": [{"value": "Supporting & Related Material", "label": "Supporting & Related Material", "count": 13, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2012-D-0307&posted_year=2017&document_type=Supporting+%26+Related+Material", "selected": false}, {"value": "Notice", "label": "Notice", "count": 1, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2012-D-0307&posted_year=2017&document_type=Notice", "selected": false}, {"value": "Other", "label": "Other", "count": 1, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2012-D-0307&posted_year=2017&document_type=Other", "selected": false}], "truncated": false}, "posted_year": {"name": "posted_year", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2012-D-0307&posted_year=2017", "results": [{"value": 2017, "label": 2017, "count": 15, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2012-D-0307", "selected": true}], "truncated": false}}, "suggested_facets": [{"name": "title", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2012-D-0307&posted_year=2017&_facet=title"}, {"name": "subtype", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2012-D-0307&posted_year=2017&_facet=subtype"}, {"name": "open_for_comment", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2012-D-0307&posted_year=2017&_facet=open_for_comment"}, {"name": "posted_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2012-D-0307&posted_year=2017&_facet_date=posted_date"}, {"name": "comment_start_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2012-D-0307&posted_year=2017&_facet_date=comment_start_date"}, {"name": "comment_end_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2012-D-0307&posted_year=2017&_facet_date=comment_end_date"}, {"name": "last_modified", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2012-D-0307&posted_year=2017&_facet_date=last_modified"}], "next": null, "next_url": null, "private": false, "allow_execute_sql": true, "query_ms": 816.8629449792206, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}